View More

CUREXO Supplies "CUVIS-joint" Artificial Joint Surgery Robot to Indonesia's Largest Hospital

Expanding Global Presence with Advanced Medical Robotics Seoul, Korea – CUREXO, Inc. (CEO: Jae-Jun Lee), a leading medical robotics company, announced that it has successfully supplied its CUVIS-joint, an artificial joint surgical robot, to Indonesia's largest hospital.CUVIS-joint is designed to support surgeons in performing precise joint replacement surgeries by providing accurate preoperative planning and optimized surgical guidance. Through advanced 3D modeling, the system enables tailored surgical plans for individual patients, improving accuracy, consistency, and overall outcomes. The adoption of CUVIS-joint by Indonesia's largest hospital marks an important step in expanding access to cutting-edge robotic surgery across Southeast Asia. With the increasing demand for joint replacement procedures in the region, the introduction of this innovative solution is expected to significantly enhance surgical quality and patient recovery. A CUREXO spokesperson stated: "By supplying CUVIS-joint to Indonesia's leading hospital, we are accelerating our global expansion strategy. We will continue to strengthen our presence in international markets, providing innovative solutions that advance surgical precision and improve patient quality of life." CUREXO currently offers a diverse portfolio of advanced medical robots, including the CUVIS-spine, a spine surgical robot, and the Morning Walk, a rehabilitation robot. With proven technology and clinical performance, the company continues to solidify its leadership in the global medical robotics market.

View More

CUREXO Initiates Clinical Trials of "CUVIS-Spine" for National Health Insurance Reimbursement in Korea

Designated as Innovative Medical Technology in April 2024; First Clinical Trial Successfully Conducted at Severance HospitalSeoul, Korea – April 11, 2024 – CUREXO, Inc. (CEO: Jae-Jun Lee), a leading medical robotics company, announced that its spine surgical robot, CUVIS-Spine, has been successfully utilized in its first clinical trial at Severance Hospital, Seoul.CUVIS-spine was designated as an Innovative Medical Technology in April 2024 by the National Evidence-based Healthcare Collaborating Agency (NECA). The designation allows advanced technologies with high potential and innovation to be introduced into clinical practice under certain conditions, facilitating early market entry and evaluation.The trial at Severance Hospital marks the first clinical case conducted under this designation and represents a critical milestone toward securing national health insurance reimbursement. Additional clinical trials are also planned at Pusan National University Yangsan Hospital, with IRB approval procedures currently underway.Designed to assist surgeons in accurately guiding and securing pedicle screws, CUVIS-spine integrates advanced 3D imaging devices (O-arm, 3D C-arm) and 2D imaging devices (C-arm). The system offers significant advantages over conventional methods, including: Enhanced pedicle screw placement accuracy Reduced surgical time Shortened patient recovery period A CUREXO spokesperson commented: "Through clinical trials at leading tertiary hospitals, we aim to accelerate the registration of CUVIS-spine as a new medical technology and its inclusion in the national health insurance system. Having obtained approvals from the U.S. FDA, European CE, and Korean MFDS, the safety and efficacy of CUVIS-spine are already validated globally. We are confident that this technology will drive meaningful innovation in spine surgery both in Korea and worldwide." In addition to CUVIS-spine, CUREXO also offers the CUVIS-joint, an artificial joint surgical robot, and the Morning Walk, a rehabilitation robot. The company continues to strengthen its presence in the global medical robotics market through advanced technology and proven clinical performance.

View More

CUREXO and The University of Texas Medical Branch Jointly Develop World's First Propulsion Force Feedback System for Rehabilitation Robots

• Real-time ground reaction force feedback helps improve gait symmetry in patients with moderate to severe impairments • Immersive VR-based training enhances patient engagement and motivation CUREXO, a leading medical robotics company (CEO Jaejun Lee), announced that it has co-developed a new Propulsion Force Feedback (PFF) system for its gait rehabilitation robot MORNINGWALK, in collaboration with The University of Texas Medical Branch (UTMB). This groundbreaking feature is the world's first system to provide real-time analysis of anterior-posterior ground reaction force (GRF), offering patients intuitive feedback on their gait propulsion.< Propulsion Force Feedback System > The newly developed PFF system is designed to move beyond conventional passive rehabilitation methods, enabling patients to engage in more active and goal-oriented training. It is particularly effective for stroke patients who typically exhibit significantly reduced GRF. By enhancing propulsion on the affected (hemiparetic) side, the system helps restore gait symmetry and improve walking stability. In addition, the system incorporates an interactive VR-based training program, transforming repetitive rehab exercises into an engaging, game-like experience. Patients can visually monitor their propulsion force in real time and make immediate adjustments, maximizing the effectiveness of each session.< VR System > "Gait propulsion is not only a measure of mobility but also a key indicator of a patient's ability to return to independent daily life," said a CUREXO spokesperson. "With the MORNINGWALK PFF system, medical professionals can design more precise rehabilitation strategies while patients train with increased motivation and enjoyment."The MORNINGWALK is an end-effector type gait rehabilitation robot, which assists lower limb joints through a powered footplate system. It is currently being utilized in major hospitals across South Korea and internationally recognized medical institutions.

View More

Participation in the 4th What's New in Robotics Surgery… Hip Surgery Robot Unveiled

• From Knee Replacement to Hip Replacement… Expansion of Orthopedic Surgical Robot Platform • Proven Precision and Safety Based on Over 30,000 Accumulated Surgeries Medical robotics company CUREXO (CEO Jaejun Lee) announced its participation in the 4th Robotic Joint Replacement Surgery Symposium, held on the 31st at Dragon City in Yongsan, Seoul.The symposium, hosted by the Korean Society for Computer Assisted Orthopaedic Surgery (CAOS Korea), consisted of five sessions and 19 lectures by leading experts in orthopedic surgery. It served as a platform to share trends and clinical experiences in robotic joint replacement surgery both domestically and internationally.CUREXO showcased its hip surgery robot, CUVIS-Joint THA, at the event, conducting demonstrations for medical professionals. Sanghoon Lee, Director of CUREXO's Technology Research Center, participated as a presenter in Session 1, where he introduced the company's flagship products, clinical data, and future technology development plans. Director Lee stated, "CUREXO has expanded the application of its robotic platform from knee replacement to now include hip replacement surgery." He emphasized that "CUVIS-Joint has demonstrated its precision and safety with more than 30,000 surgeries performed globally." The CUVIS-Joint THA robot analyzes 3D anatomical data in detail to a personalized surgical plan. During surgery, its real-time tracking and automatic correction features minimize deviations from the surgical plan, allowing for precise implantation of the artificial joint. Currently, CUVIS-Joint is actively being adopted and utilized not only in major general hospitals in Korea but also in medical institutions in India, Malaysia, Indonesia, and other countries.

View More

CUVIS Spine Successfully Performs First Spinal Surgery in Malaysia

• Successful Spinal Surgeries Performed with CUVIS Spine at KPJ Ipoh Specialist Hospital in Malaysia• Following the Joint Surgery Robot CUVIS Joint, Spinal Robot Now Supplied – Expanding Presence in the Malaysian MarketCUREXO, a medical robotics company, announced on the 27th that its spinal surgery robot, CUVIS Spine, was successfully utilized in two spinal surgeries at a local hospital in Malaysia. The surgeries were conducted at KPJ Ipoh Specialist Hospital located in the state of Perak, Malaysia. The hospital had previously adopted CUREXO's joint replacement robot, CUVIS Joint, and with the recent introduction of CUVIS Spine, the company has further solidified its presence within the hospital. CUREXO stated that the spinal surgeries were completed successfully, receiving positive evaluations in terms of both safety and precision. CUVIS Spine, developed with CUREXO's own technology, enables preoperative surgical planning and features a high-precision robotic arm and real-time navigation tools, allowing for faster, more convenient, and more accurate surgeries compared to conventional manual procedures.CUVIS Spine received regulatory approvals from Korea's MFDS in 2019, followed by Europe's CE and the U.S. FDA, and is currently being used in major hospitals both domestically and internationally. It has also been designated as an innovative medical technology and is undergoing evaluation at Severance Hospital and Pusan National University Yangsan Hospital for inclusion in the Korean national health insurance system. A CUREXO representative stated, "The successful application of CUVIS Spine in real surgeries at a Malaysian hospital is highly meaningful. Building on this case, we plan to accelerate the expansion of spinal surgery robots across the Southeast Asian market."

View More

JOA 2025

• CUVIS-Joint: Japanese PMDA-Approved Robotic Joint Surgery System Introduced• Expanding Collaboration with Japanese Medical Professionals at JOA 2024 in Tokyo (May 22–25) CUREXO Inc. (KOSDAQ: 060280), a medical robotics company, announced on May 22 that it is participating in the Japanese Orthopaedic Association (JOA) annual meeting being held in Tokyo from May 22 to 25. The JOA meeting is Japan's largest orthopedic academic event, bringing together experts in orthopedic research, treatment, and surgical outcomes, with over 20,000 members in attendance. At the event, CUREXO is showcasing its robotic joint surgery system CUVIS-Joint to local medical professionals through its Japanese partner, KYOCERA. In March, CUREXO received manufacturing and sales approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA), paving the way for official market entry. The company also secured an exclusive sales agreement with the KYOCERA Group for the Japanese market.A CUREXO official stated, "Based on our partnership with KYOCERA, we aim to strengthen collaboration with hospitals and medical professionals in Japan and gradually expand our market share in the Japanese medical robotics industry."

View More

MDSAP Certification

•  Accelerating Global Expansion in the Medical Robotics Market by Enhancing Product Credibility and Regulatory EfficiencyCUREXO, a medical robotics company led by CEO Jae-Jun Lee, announced on the 21st that it has obtained MDSAP (Medical Device Single Audit Program) certification, which integrates regulatory audits for five major countries : the United States, Canada, Japan, Australia, and Brazil.MDSAP allows medical device manufacturers to undergo a single regulatory audit that satisfies the quality management requirements of all five participating countries. This certification significantly streamlines the approval process, as it can replace or reduce the need for individual audits in each country.With the MDSAP certification, CUREXO has not only strengthened the credibility of its product quality but also reduced the time and cost required for obtaining regulatory approvals in each target market. The certification is expected to serve as a critical turning point in the company's efforts to expand strategically into global markets.A CUREXO official stated, "We are continuously expanding regulatory approvals across key global markets. The MDSAP certification will not only support our entry into new export regions but also enhance trust among our international partners."

View More

Approval from Japan's PMDA

On March 17, CUREXO received approval from Japan's Pharmaceuticals and Medical Devices Agency(PMDA) for the manufacturing and sales of CUVIS-joint, a robotic system for artificial joint surgery. As a result, We will begin sales of the CUVIS-joint in Japan through KYOCERA Global, who holds the exclusive distribution rights in the country.

View More

AAOS 2025

• Unveil CUVIS-Joint THA for Hip Surgery at AAOS 2025• Operate Independent Booth at World's Largest Orthopedic Conference in San DiegoCUREXO Inc. (KOSDAQ: 060280), a leading medical robotics company, announced that it will operate its own booth at the American Academy of Orthopaedic Surgeons (AAOS) 2025 in San Diego. At this global event, CUREXO will introduce its newly developed CUVIS-Joint THA robotic system for total hip arthroplasty, alongside its established robotic systems for joint and spine surgeries—CUVIS-Joint and CUVIS-Spine. The CUVIS-Joint THA is specifically engineered to enhance the precision of implant placement in hip replacement surgeries. It offers customized simulation based on the individual patient's anatomy, beginning from the surgical planning stage. At AAOS 2025, Curexo plans to actively promote global expansion by conducting live product demonstrations and engaging in meetings with healthcare professionals and international distributors. Currently, CUREXO  exports its CUVIS-Joint, CUVIS-Spine, and Morning Walk rehabilitation robots primarily to India, and is expanding to markets including Russia, Taiwan, Pakistan, Indonesia, and Malaysia. CUREXO is also accelerating its entry into the North American and Japanese markets. A CUREXO official stated, "Through our participation in AAOS 2025, we aim to globally showcase our advanced medical robotics technology and expand our regulatory approvals and export destinations. We are committed to strengthening our international distributor network and increasing our global market share."